↓ Skip to main content

Dove Medical Press

Article Metrics

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis

Overview of attention for article published in Drug Design, Development and Therapy, January 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
1 tweeter
patent
1 patent
wikipedia
1 Wikipedia page

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
59 Mendeley
Title
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
Published in
Drug Design, Development and Therapy, January 2016
DOI 10.2147/dddt.s82599
Pubmed ID
Authors

Vito Di Lernia, Federico Bardazzi

Abstract

The outlook for patients with psoriasis has improved significantly over the last 10 years with the introduction of targeted therapies. Cytokines exert their effects by activating intracellular signaling and transcription pathways, among which there are Janus kinases (JAKs) and signal transducers and activators of transcription (STAT) pathways. JAKs are intracellular second messengers that are crucial for transmitting extracellular cytokine signals to the cell. JAK inhibition interrupts intracellular signaling and can suppress immune cell activation and inflammation in T-cell-mediated disorders, such as psoriasis. Consequently, JAKs are the subject of intensive research activity, since they represent possible therapeutic targets. Tofacitinib is an orally available compound belonging to a novel category of nonbiologic drugs, the "JAK inhibitors", which target JAKs. Recently, oral and topical formulations of tofacitinib have been demonstrated to be safe and effective for the treatment of plaque psoriasis in randomized clinical trials. In particular, a 10 mg bid dose of tofacitinib was shown to be noninferior to etanercept 50 mg subcutaneously twice weekly. Questions remain unresolved regarding the safety risk beyond the 5 mg bid dose. This review, assessing the available scientific literature, focuses on the profile of tofacitinib, as investigational compound in the treatment of plaque psoriasis. An overview of the efficacy and safety data from randomized clinical trials is provided. In addition, the authors highlight future potential applications of tofacitinib in other skin diseases, in particular alopecia areata and vitiligo.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Denmark 1 2%
Unknown 58 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 14 24%
Researcher 8 14%
Other 6 10%
Student > Doctoral Student 5 8%
Student > Ph. D. Student 5 8%
Other 13 22%
Unknown 8 14%
Readers by discipline Count As %
Medicine and Dentistry 26 44%
Agricultural and Biological Sciences 6 10%
Pharmacology, Toxicology and Pharmaceutical Science 5 8%
Biochemistry, Genetics and Molecular Biology 4 7%
Immunology and Microbiology 3 5%
Other 6 10%
Unknown 9 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 May 2018.
All research outputs
#2,266,693
of 12,953,360 outputs
Outputs from Drug Design, Development and Therapy
#124
of 1,368 outputs
Outputs of similar age
#67,494
of 335,512 outputs
Outputs of similar age from Drug Design, Development and Therapy
#10
of 86 outputs
Altmetric has tracked 12,953,360 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,368 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,512 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.